BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Clinical Outcome
20 results:

  • 1. A methylation- and immune-related lncRNA signature to predict ovarian cancer outcome and uncover mechanisms of chemoresistance.
    Chen L; Gao W; Lin L; Sha C; Li T; Chen Q; Wei H; Yang M; Xing J; Zhang M; Zhao S; Xu W; Li Y; Long L; Zhu X
    J Ovarian Res; 2023 Sep; 16(1):186. PubMed ID: 37674251
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    Ma H; Chen X; Mo S; Mao X; Chen J; Liu Y; Lu Z; Yu S; Chen J
    Theranostics; 2023; 13(13):4601-4614. PubMed ID: 37649613
    [No Abstract]    [Full Text] [Related]  

  • 3. Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights.
    Balsano R; Zanuso V; Pirozzi A; Rimassa L; Bozzarelli S
    Curr Oncol; 2023 Mar; 30(4):3871-3885. PubMed ID: 37185406
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Low plasma pd-l1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
    Fanale D; Brando C; Corsini LR; Cutaia S; Di Donna MC; Randazzo U; Filorizzo C; Lisanti C; Magrin L; Gurrera V; Romano R; Dimino A; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Giordano A; Chiantera V; Russo A; Bazan V; Iovanna JL
    BMC Cancer; 2023 May; 23(1):437. PubMed ID: 37179293
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. TIMEAS, a promising method for the stratification of testicular germ cell tumor patients with distinct immune microenvironment, clinical outcome and sensitivity to frontline therapies.
    Meng J; Gao J; Li X; Gao R; Lu X; Zhou J; Yan F; Wang H; Liu Y; Hao Z; Zhang X; Liang C
    Cell Oncol (Dordr); 2023 Jun; 46(3):745-759. PubMed ID: 36823338
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. PTEN Deficiency in Tubo-Ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification.
    Zhang X; Wang A; Han L; Liang B; Allard G; Diver E; Howitt BE
    Mod Pathol; 2023 May; 36(5):100106. PubMed ID: 36805789
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.
    Yu S; Yang R; Xu T; Li X; Wu S; Zhang J
    Gynecol Oncol; 2022 Nov; 167(2):342-353. PubMed ID: 36114029
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Construction of an Immune Cell Infiltration Score to Evaluate the Prognosis and Therapeutic Efficacy of Ovarian cancer Patients.
    Liu J; Wang Y; Yuan S; Wei J; Bai J
    Front Immunol; 2021; 12():751594. PubMed ID: 34745124
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Application of Immunoprofiling Using Multiplexed Immunofluorescence Staining Identifies the Prognosis of Patients with High-Grade Serous Ovarian cancer.
    Lee SW; Lee HY; Kang SW; Kim MJ; Lee YJ; Sung CO; Kim YM
    Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502561
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma.
    Shi Z; Zhao Q; Lv B; Qu X; Han X; Wang H; Qiu J; Hua K
    Clin Transl Med; 2021 May; 11(5):e399. PubMed ID: 34047476
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. PD-1 and pd-l1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome.
    Bekos C; Pils D; Dekan S; Hofstetter G; Horak P; Reinthaller A; Polterauer S; Schwameis R; Aust S
    Sci Rep; 2021 Mar; 11(1):6400. PubMed ID: 33737722
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9.
    Rodriguez E; Boelaars K; Brown K; Eveline Li RJ; Kruijssen L; Bruijns SCM; van Ee T; Schetters STT; Crommentuijn MHW; van der Horst JC; van Grieken NCT; van Vliet SJ; Kazemier G; Giovannetti E; Garcia-Vallejo JJ; van Kooyk Y
    Nat Commun; 2021 Feb; 12(1):1270. PubMed ID: 33627655
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Liverani C; Bongiovanni A; Mercatali L; Pieri F; Spadazzi C; Miserocchi G; Di Menna G; Foca F; Ravaioli S; De Vita A; Cocchi C; Rossi G; Recine F; Ibrahim T
    Endocr Pathol; 2021 Jun; 32(2):309-317. PubMed ID: 33409812
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
    Lee EK; Xiong N; Cheng SC; Barry WT; Penson RT; Konstantinopoulos PA; Hoffman MA; Horowitz N; Dizon DS; Stover EH; Wright AA; Campos SM; Krasner C; Morrissey S; Whalen C; Quinn R; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Oct; 159(1):72-78. PubMed ID: 32771276
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. HDAC Inhibition Induces pd-l1 Expression in a Novel Anaplastic Thyroid cancer Cell Line.
    Hegedűs L; Rittler D; Garay T; Stockhammer P; Kovács I; Döme B; Theurer S; Hager T; Herold T; Kalbourtzis S; Bankfalvi A; Schmid KW; Führer D; Aigner C; Hegedűs B
    Pathol Oncol Res; 2020 Oct; 26(4):2523-2535. PubMed ID: 32591993
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome.
    Wolf D; Fiegl H; Zeimet AG; Wieser V; Marth C; Sprung S; Sopper S; Hartmann G; Reimer D; Boesch M
    Int J Cancer; 2020 Apr; 146(7):2007-2018. PubMed ID: 31800094
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
    Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
    Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Anti-pd-l1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.
    Mandai M; Hamanishi J; Abiko K; Matsumura N; Baba T; Konishi I
    Int J Clin Oncol; 2016 Jun; 21(3):456-61. PubMed ID: 26968587
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (pd-l1) in testicular germ cell tumors.
    Cierna Z; Mego M; Miskovska V; Machalekova K; Chovanec M; Svetlovska D; Hainova K; Rejlekova K; Macak D; Spanik S; Ondrus D; Kajo K; Mardiak J; Babal P
    Ann Oncol; 2016 Feb; 27(2):300-5. PubMed ID: 26598537
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Semi mature blood dendritic cells exist in patients with ductal pancreatic adenocarcinoma owing to inflammatory factors released from the tumor.
    Tjomsland V; Spångeus A; Sandström P; Borch K; Messmer D; Larsson M
    PLoS One; 2010 Oct; 5(10):e13441. PubMed ID: 20976171
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.